Navigation Links
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
Date:8/5/2009

liabilities, net 1,596 31,433 7,218 43,177 Gain (loss) on exchange of convertible notes 7,201 (3,313) 7,201 (5,608) Equity loss from investment in joint venture - - (1,204) - Settlement expense (3,198) - (3,368) - Write-off of financing arrangement costs - (2,361) - (2,361) --- ------ --- ------ Net loss before noncontrolling interest (18,090) (58,054) (33,146) (96,250) Noncontrolling interest 63 31 152 63 --- --- --- --- Net loss attributable to CTI (18,027) (58,023) (32,994) (96,187) Gain on restructuring of preferred stock - - 2,116 - Preferred stock dividends (1) (226) (24) (468) Deemed dividends on preferred stock (9,398) (1,067) (9,648) (17,265) ------ ------ ------ ------- Net loss attributable to CTI common shareholders $(27,426) $(59,316) $(40,550) $(113,920) ======== ======== ======== ========= Basic and diluted net loss per common share $(0.06) $(5.18) $(0.11) $(12.28) ====== ====== ====== ======= Shares used in calculation of basic and diluted net loss per common share (1) 446,174 11,447 366,293 9,277 ======= ====== ======= ===== Balance Sheet Data: (amounts in thou
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 1000 balances – 4 ... on customers’ weighing needs and expertly narrows down the ... balances, scales or even terminals. , First, select ... weight (or select readability instead) and define the accuracy ... selection criteria narrows down the list to models that ...
(Date:7/24/2014)... Draper University, a top program ... announce that for 6 weeks this summer, 39 ... on the Draper University campus in the heart ... focused on entrepreneurship, building real-world skills, and “learning ... its sixth cohort, continues to refresh its curriculum ...
(Date:7/24/2014)... July 24, 2014   Cypher Genomics, Inc., ... appointment of Adam Simpson as president ... rapid and comprehensive annotation and interpretation of individual ... "Cypher,s technology has the potential to ... enhancing diagnostic accuracy, optimizing therapeutic approaches and reducing ...
(Date:7/24/2014)... San Diego, CA (PRWEB) July 24, 2014 ... in the reporting of molecular diagnostic test results. ... tracking capabilities necessary for the validation and reporting ... in oncology. Molecular diagnostics is a rapidly growing ... for infectious disease, genetic predisposition, cancer, and companion ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2
... , , , , ... Primer anneal. temp. , Sensitivity , Specifi- , ... Tolerance , of non- , specific RNA , ... of serum components , Carry-over , prevention ...
... amplification of up to 3 kb genomic , DNA targets Cat. No. 1 647 679 ... 647 687 4 x 250 units (1 unit/l) , Cat. No. 1 146 165 100 ... Cat. No. 1 418 432 4 x 250 units (5 units/l) , ... 1 435 094 20 x 250 units (5 units/l) , , , , ...
... , Explore New Horizons in Amplification Yield, , ... High Yield, Accuracy, and the Prevention , of Carry-Over Contamination ... Roche Applied Science, which pioneered the blending , ... Long Template PCR Systems, now introduces the Expand High FidelityPLUS PCR , ...
Cached Biology Technology:Reverse transcriptases suitable for one-step RT-PCRb 2Taq DNA Polymerase 2Taq DNA Polymerase 3Expand High FidelityPLUS PCR System 2Expand High FidelityPLUS PCR System 3
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... provide much higher yield than their homozygous parents. Plant ... and used this effect called heterosis for richer harvests. ... underlying this phenomenon. Researchers at the University of Bonn ... decoded one possible mechanism in corn roots. More genes ...
... are known to be prodigious jumpers on land. Now, researchers ... , a Cell Press publication, have found that the tiny ... water, too. Their secret is a series of spring-loaded, oar-like ... have solved the most difficult task of jumping from the ...
... Grumman Corporation (NYSE: NOC ) has successfully ... biometric information system (ABIS) for the Australian Department of ... period to enable testing and refinement of analytical techniques ... the requirements for a future biometrics information management solution. ...
Cached Biology News:Corn: Many active genes - high yield 2Corn: Many active genes - high yield 3Pygmy mole crickets don't just walk on water, they jump on it 2Northrop Grumman Delivers Australian Automated Biometric Information System Trial Proof of Concept 2
Tube-O-DIALYZER Floats, small....
Feline Rhinotracheitis Virus...
Ezrin/Radixin/Moesin Antibody...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: